New Market Research Report "Global and China Tire Mold Industry Report, 2012-2015" Has Been Added In MarketResearchReports.Biz's Reports Database
Albany, NY -- (SBWIRE) -- 05/07/2013 -- Since 2011, the global tire market, especially the Chinese tire market, has seen slow growth, which directly impacts the market demand for tire molds.
In 2012, China tire mold industry harvested the revenue of RMB3.01 billion or so, including RMB1.87 billion from automotive tire molds, only up 0.16% year on year.
In terms of profitability, the performance of most Chinese tire mold manufacturers declined in 2012. During the first three quarters of 2012, Himile's revenue only increased by 0.37% year on year, and its net income fell by 6.28%. Meanwhile, the growth rate of Greatoo also slowed down, with the revenue being the same with that in the same period in 2011 and net income up by5.92%.
Among other non-listed companies, the revenue of Shandong Dawang Jintai dropped by 21.77% year on year in 2012, and that of Yuantong witnessed a year-on-year decline of 12.26%.
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/167438
Seen from new construction project, there were merely two major tire mold projects in 2012: the tire mold project co-invested with a total capital of RMB1.1 billion by Henan Yasheng and Jiaozuo Deke Mould; and the 300-set radial tire mold virtual manufacturing technology project of Shandong Dawang Jintai.
In the projects invested and built before 2012, Himile's “precise radial tire mold construction project” is delayed until the end of September 2013 instead of the planned December 2012, with the investment of RMB349 million. Greatoo's “large-sized engineering vehicle tire and special tire mold expansion project” is under construction; the project aims at the mold market of military SUV tires, aerospace tires, racing tires, snow tires, high-grade sedan tires, etc, with huge market potentials. With total investment of RMB197 million; the project is expected to be put into production in July 2013.
Although the current tire mold industry is sluggish, we expect that China's domestic demand for tire molds will grow at the average annual growth rate of around 7% with the moderate recovery of Chinese automobile market in the next 2-3 years.
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis-details/global-and-china-tire-mold-industry-report-2012-2015
The report highlights the followings:
Development, competition and future development trends of the global tire mold industry;
Major policies, operation, supply and demand, market competition and outlook of China tire mold industry;
Main products, operation and development planning of major producers worldwide;
Major products, capacity, operation, major customers, project planning and performance prediction of major Chinese manufacturers.
Global Endocrinology Drugs Market 2012-2016 : http://www.marketresearchreports.biz/analysis/160192
TechNavio's report, the Global Endocrinology Drugs Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Endocrinology Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Abbott Laboratories, Eli Lilly and Co., Novartis AG, and Pfizer Inc.
The other vendors mentioned in the report are Acrux Ltd, Alacer Corp., Alcon Inc., ChemGen Corporation., Excaliard Pharmaceuticals Inc, F. Hoffmann La Roche, Facet Biotech Corporation, Ferrosan Holding A/S, FoldRx Pharmaceuticals Inc., Genoptix Inc., Janssen Pharmaceutica NV, King Pharmaceuticals Inc., Laboratorio Teuto Brasileiro S.A., NextWave Pharmaceuticals Inc., Novo Nordisk A/S, Pharmacia Corporation, Piramal Healthcare Limited, Solvay Pharmaceuticals Inc., STARLIMS Technologies Ltd., and Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
Global Non-small Cell Lung Cancer Drugs Market 2012-2016 : http://www.marketresearchreports.biz/analysis/160191
TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 2.77 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Ophthalmic Drugs market has also been witnessing the trend of emergence of personalized medicines. However, the increasing use of complementary and alternative medicine could pose a challenge to the growth of this market.
TechNavio's report, the Global Non-small Cell Lung Cancer Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948